Broadly neutralizing antibody and the HIV reservoir in acute HIV infection: A strategy toward HIV remission?

Current Opinion in HIV and AIDS

Volumn 10, Issue 3, 2015, Pages 198-206

  Ananworanich, Jintanat ^a,b   McSteen, Brian ^a,b   Robb, Merlin L ^a,b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

antibody; broadly neutralizing antibody; early antiretroviral therapy; HIV DNA; HIV reservoir; Keywords acute HIV infection; replication competent virus

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BROADLY NEUTRALIZING ANTIBODY; HISTONE DEACETYLASE INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LATENCY REVERSING AGENT; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; MACACA; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; REMISSION; REVIEW; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIREMIA; VIRUS ENTRY; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MOUSE; VIROLOGY;

ANIMALS; ANTI-RETROVIRAL AGENTS; ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MICE;

EID: 84928564710     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000144     Document Type: Review

References (41)

1. Hansen SG, Ford JC, Lewis MS, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011; 473:523-527.
2. Shingai M, Nishimura Y, Klein F, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013; 503:277-280.
3. Barouch DH, Whitney JB, Moldt B, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013; 503:224-228.
4. Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication. Science 2014; 345:169-174.
5. Lam S, Bollard C. T-cell therapies for HIV. Immunotherapy 2013; 5:407-414.
6. Horwitz JA, Halper-Stromberg A, Mouquet H, et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci USA 2013; 110:16538-16543.
7. Klein F, Halper-Stromberg A, Horwitz JA, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012; 492:118-122.
8. Halper-Stromberg A, Lu CL, Klein F, et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 2014; 158:989-999.
9. Okoye AA, Picker LJ. CD4 T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev 2013; 254:54-64.
10. D'Souza M, Fontenot AP, Mack DG, et al. Programmed death 1 expression on HIV-specific CD4 T cells is driven by viral replication and associated with T cell dysfunction. J Immunol 2007; 179:1979-1987.
11. Doitsh G, Galloway NL, Geng X, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 2014; 505:509-514.
12. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
13. Chun TW, Engel D, Berrey MM, et al. Early establishment of a pool of latently infected, resting CD4 T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998; 95:8869-8873.
14. Whitney JB, Hill AL, Sanisetty S, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 2014; 512:74-77.
15. Okoye AA, Rohankhedkar M, Reyes M, et al. Early treatment in acute SIV infection limits the size and distribution of the viral reservoir. In: Conference on Retroviruses and Opportunistic Infections (internet). Boston, MA: 2014.
16. Ananworanich J, Fletcher JL, Pinyakorn S, et al. A novel acute HIV infection staging system based on 4th generation immunoassay. Retrovirology 2013; 10:56.
17. Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multitargeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 2012; 7:e33948.
18. Ananworanich J, Vandergeeten C, Chomchey N, et al. Early ART intervention restricts the seeding of the HIV reservoir in long-lived central memory CD4 T cells. In: 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA: 2013.
19. Buzon MJ, Martin-Gayo E, Pereyra F, et al. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J Virol 2014; 88:10056-10065.
20. Chun TW, Justement JS, Moir S, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 2007; 195:1762-1764.
21. Markowitz M, Evering TH, Garmon D, et al. A randomized open-label study of 3-versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals. J Acquir Immune Defic Syndr 2014; 66:140-147.
22. Archin NM, Vaidya NK, Kuruc JD, et al. Immediate antiviral therapy appears to restrict resting CD4 cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci USA 2012; 109:9523-9528.
23. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Posttreatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog 2013; 9:e1003211.
24. Descours B, Avettand-Fenoel V, Blanc C, et al. Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. Clin Infect Dis 2012; 54:1495-1503.
25. West AP Jr, Scharf L, Scheid JF, et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 2014; 156:633-648.
26. Chun TW, Murray D, Justement JS, et al. Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir. Proc Natl Acad Sci USA 2014; 111:13151-13156.
27. Study of the safety and pharmacokinetics of a human monoclonal antibody, VRC-HIVMAB060-00-AB(VRC01) administered intravenously or subcutaneously to healthy adults. In: ClinicalTrials.gov (Internet). Bethesda, MD: National Library of Medicine (US); 2000-2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01993706?termNCT01993706&rank1. NCT01993706. Accessed 11 November 2014.
28. VRC 601: A phase I, open-label, dose-escalation study of the safety and pharmacokinetics of a human monoclonal antibody, VRC HIVMAB060-00-AB (VRC01), with broad HIV-1 neutralizing activity, administered intravenously or subcutaneously to HIV-infected. In: ClinicalTrials.gov (Internet). Bethesda, MD: National Library of Medicine (US); 2000-2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01950325?termNCT01950325&rank1 NCT01950325. Accessed 11 November 2014.
29. A phase 1, open label, dose-escalation study of the safety, pharmacokinetics and antiretroviral activity of 3BNC117 monoclonal antibody in HIV-infected and HIV-uninfected volunteers. In: ClinicalTrials.gov (Internet). Bethesda, MD: National Library of Medicine (US); 2000-2014. Available from: http://clinicaltrials.gov/ct2/show/NCT02018510?termNCT02018510&rank1. NCT02018510. Accessed 11 November 2014.
30. Soriano-Sarabia N, Bateson RE, Dahl NP, et al. Quantitation of replicationcompetent HIV-1 in populations of resting CD4 T cells. J Virol 2014; 88:14070-14077.
31. Ho YC, Shan L, Hosmane NN, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013; 155:540-551.
32. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013; 369:1828-1835.
33. National Institute of Allergy and Infectious Diseases (NIAID) (http://www. niaid.nih.gov/news/newsreleases/2014/pages/mississippibabyhiv.aspx). Access date 11 November 2014.
34. Henrich TJ, Hanhauser E, Marty FM, et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med 2014; 161:319-327.
35. Liu M, Yang G, Wiehe K, et al. Polyreactivity and autoreactivity among HIV-1 antibodies. J Virol 2014; 89:784-798.
36. Williams JP, Hurst J, Stohr W, et al. HIV-1 DNA predicts disease progression and posttreatment virological control. Elife 2014; 3:e03821.
37. Chun TW, Justement JS, Murray D, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. Aids 2010; 24:2803-2808.
38. Hill AL, Rosenbloom DI. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci USA 2014; 111:13475-13480.
39. Benen TD, Tonks P, Kliche A, et al. Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein. J Biomed Sci 2014; 21:79.
40. Balazs AB, Ouyang Y, Hong CM, et al. Vectored immunoprophylaxis protects humanized mice frommucosal HIV transmission. Nat Med 2014; 20:296-300.
41. Hü tter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692-698.